Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Nováková, I., Zapletalova, O., Piková, J., Ambler, Z. · 2010 · Neurological Research

Abstract

Background Muscle spasticity is common in multiple sclerosis (MS), occurring in more than 60% of patients. Objective To compare Sativex with placebo in relieving symptoms of spasticity due to MS. Methods A 15-week, multicenter, double-blind, randomized, placebo-controlled, parallel-group study in 337 subjects with MS spasticity not fully relieved with current anti-spasticity therapy. Results The primary endpoint was a spasticity 0-10 numeric rating scale (NRS). Intention-to-treat (ITT) analysis showed a non-significant improvement in NRS score, in favor of Sativex. The per protocol (PP) population (79% of subjects) change in NRS score and responder analyses (> or =30% improvement from baseline) were both significantly superior for Sativex, compared with placebo: -1.3 versus -0.8 points (change from baseline, p=0.035); and 36% versus 24% (responders, p=0.040). These were supported by the time to response (ITT: p=0.068; PP: p=0.025) analyses, carer global impression of change assessment (p=0.013) and timed 10-meter walk (p=0.042). Among the subjects who achieved a > or =30% response in spasticity with Sativex, 98, 94 and 73% reported improvements of 10, 20 and 30%, respectively, at least once during the first 4 weeks of treatment. Sativex was generally well tolerated, with most adverse events reported being mild-to-moderate in severity. Discussion and conclusions The 0-10 NRS and responder PP analyses demonstrated that Sativex treatment resulted in a significant reduction in tr…

Overview

Integrity signals

Registry

Crossref · 10.1179/016164109x12590518685660

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Research works printed but not linked: 2

  1. Wade D, 2004, Mult Scler, 10, 1
  2. Mahoney Fl, 1965, Maryland State Med J, 14, 56

Cited by

See all 305

Metadata

Authors
Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Nováková, I., Zapletalova, O., Piková, J., & Ambler, Z.
Affiliations
Royal Berkshire Hospital (GB)
Venue
Neurological Research
Published
2010-06
Volume
32
Issue
5
Pages
451-459
ISSN
  • 0161-6412 (ISSN-L)
  • 1743-1328
OpenAlex
W2043053000
Cited by
283
References
35
Citations by year
2026: 9 · 2025: 7 · 2024: 16 · 2023: 15 · 2022: 24 · 2021: 17 · 2020: 26 · 2019: 14 · 2018: 31 · 2017: 23 · 2016: 18 · 2015: 16 · 2014: 24 · 2013: 10 · 2012: 21
FWCI
8.19
Type
journal article
Language
en
Open access
closed
Locations
  • Neurological Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Keywords
Sativex, nabiximols, multiple sclerosis, spasticity, cannabis-based medicines, responder analysis, adverse events, tolerability
MeSH terms
Mental Disorders, Cannabidiol, Double-Blind Method, Drug Combinations, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Sclerosis, Muscle Spasticity, Neuromuscular Agents, Plant Extracts, Severity of Illness Index, Dronabinol, Time Factors, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. https://app.cochat.ai/papers/10.1179/016164109x12590518685660
The paper
Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Nováková, I., Zapletalova, O., Piková, J., & Ambler, Z. (2010). A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurological Research. https://doi.org/10.1179/016164109x12590518685660

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.